Loading organizations...
§ Private Profile · Vancouver, Canada
Reverb Therapeutics is a technology company.
Reverb Therapeutics develops novel medicines that intelligently reshape the body's immune system to combat cancer and other serious conditions. Its core platform, Amplify•R™, utilizes bispecific antibodies to modulate and redirect the body's natural cytokine signals, enhancing the function of immune cells like T and NK cells. This approach aims to achieve potent anti-tumor activity by rewiring the immune system, leveraging computational modeling and AI-guided optimization to deliver targeted immune activation without the systemic toxicity often associated with external cytokine treatments.
The company was co-founded by David de Graaf, Ph.D., who serves as Chief Executive Officer, and Surjit Dixit, Ph.D., the Chief Scientific Officer. Dr. de Graaf brings extensive leadership experience from various biotech ventures, including Abcuro and Syntimmune, with a background in genetics. Dr. Dixit, a seasoned drug developer, previously led the scientific direction at Zymeworks Inc., where he pioneered the AZYMETRIC™ bispecific platform, contributing deep expertise in rational molecular design. Their combined insight recognized the potential to harness endogenous immune signals for smarter therapeutic intervention.
Reverb Therapeutics focuses on developing treatments for patients suffering from life-threatening diseases, particularly within oncology and autoimmune disorders. The company's vision is to advance its Amplify•R™ platform to create therapies that enable the body to fight disease more effectively, redirecting its innate defenses to achieve meaningful clinical outcomes. This long-term objective underscores a commitment to transforming how immune-mediated conditions are addressed.
Reverb Therapeutics has raised $12.0M across 1 funding round.
Reverb Therapeutics has raised $12.0M in total across 1 funding round.
Reverb Therapeutics has raised $12.0M in total across 1 funding round.
Reverb Therapeutics's investors include Amplitude Ventures.
Reverb Therapeutics has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $12M Seed | Amplitude Ventures | — | Announced |
Reverb Therapeutics is a Vancouver-based preclinical biotechnology company developing bispecific antibodies via its AmplifyR™ platform to amplify natural cytokine signaling, targeting cancers and autoimmune diseases.[1][2][4] The platform redirects the body's endogenous cytokines, like IL-15, to diseased tissues, minimizing systemic toxicity while enhancing immune responses locally; it serves oncology patients with poor responses to current therapies and plans expansion to autoimmune conditions.[1][2][3][5] In seed VC stage since its 2023 founding, backed by investors including Amplitude Ventures and Myeloma Investment Fund, Reverb shows early momentum with a recent collaboration for lead candidate advancement and an AACR 2025 poster presentation signaling preclinical progress toward clinical trials within two years.[1][4]
Founded in 2023 in Vancouver, Canada, Reverb Therapeutics emerged from the vision of biotech veterans addressing limitations in cytokine therapies for cancer and immune diseases.[1][2][4] David De Graaf, PhD, co-founder, President, and CEO, brings extensive experience from leading Abcuro, Comet Therapeutics, and Syntimmune, plus roles at Apple Tree Partners, Flagship Pioneering, Pfizer, AstraZeneca, and Boehringer Ingelheim.[3][4] Surjit Dixit, PhD, co-founder and Chief Scientific Officer, leads the scientific efforts.[2][4] The idea stemmed from amplifying the body's natural immune mechanisms—particularly cytokines like IL-15—to boost therapies like PD-1 inhibitors (e.g., Keytruda) without foreign agents, gaining early traction through seed funding and a November 2024 partnership with Royalmount Laboratories for pre-IND work on its first candidate.[1][3][4]
Reverb rides the bispecific antibody and cytokine therapy wave in immuno-oncology, where limitations like toxicity and poor penetration in solid tumors create unmet needs for next-gen treatments.[1][3] Timing aligns with surging demand for targeted immunotherapies amid PD-1/PD-L1 dominance, as combos seek deeper responses in resistant cancers; market forces favor platforms using endogenous signals for safety and manufacturability.[2][3] By localizing cytokines, Reverb influences the ecosystem toward precise, body-native modulation, potentially expanding to autoimmunity and integrating with standards like Keytruda, accelerating Canada's biotech hub via local CRO collaborations.[1][4]
Reverb's preclinical momentum positions it for lead selection and IND filing in 2025-2026, with AMP-01 potentially entering trials soon to validate synergy with PD-1s.[1][3] Trends like AI-driven antibody design and combo immuno-oncology will shape progress, alongside autoimmune expansion via AMP-03.[4][5] Influence may grow through partnerships, scaling its platform to redefine cytokine utility beyond toxicity barriers—echoing its core mission to harness natural immunity for transformative therapies.[2][3]